{
    "nct_id": "NCT05132582",
    "official_title": "A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)",
    "inclusion_criteria": "* Centrally confirmed HER2+ breast carcinoma according to the 2018 American Society of Clinical Oncologists (ASCO) College of American Pathologists (CAP) guidelines prior to randomization (defined as a 3+ score on immunohistochemistry (IHC) and/or 2+ IHC and concurrent positive by ISH).\n* Have unresectable locally advanced or metastatic disease.\n\n  * If recurrent (after [neo]adjuvant therapy), must be at least 6 month treatment free from any trastuzumab and pertuzumab received in the early breast cancer setting for advanced HER2+ disease.\n* Have received 4-8 cycles of pre-study induction therapy including only trastuzumab, pertuzumab, and taxane as first-line of therapy for the treatment of advanced breast cancer prior to study enrollment. Participants are eligible provided they are without evidence of disease progression following completion of induction therapy.\n* Known hormone receptor status (per local guidelines; may be hormone receptor positive [HR+] or negative [HR-])\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* CNS Inclusion - Based on screening contrast-enhanced brain magnetic resonance imaging (MRI), participants may have any of the following:\n\n  * No evidence of brain metastases\n  * Untreated brain metastases which are asymptomatic not needing immediate local treatment and, if identified on prior brain imaging, without evidence of progression since starting first-line induction therapy with trastuzumab, pertuzumab, and taxane\n  * Previously treated brain metastases which are asymptomatic\n\n    * Brain metastases previously treated with local therapy must not have progressed since treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with any tyrosine kinase inhibitor targeting HER2 and/or epidermal growth factor receptor (EGFR) including pyrotinib, lapatinib, tucatinib, neratinib, and afatinib (except neratinib if given in extended adjuvant setting and â‰¥ 12 months have elapsed since last neratinib dose prior to start of study drug)\n* Unable to undergo contrast-enhanced MRI of the brain\n* CNS Exclusion - Based on screening brain MRI and clinical assessment\n\n  * Symptomatic brain metastasis after CNS-directed local therapy\n  * Progression of brain metastases since starting first line trastuzumab, pertuzumab, and taxane\n  * Ongoing use of systemic corticosteroids at a total daily dose of >2 mg of dexamethasone (or equivalent)\n  * Any untreated brain lesion in an anatomic site which may pose risk to participant\n  * Known or suspected leptomeningeal disease (LMD)\n  * Poorly controlled (>1/week) seizures, or other persistent neurologic symptoms",
    "miscellaneous_criteria": ""
}